bioLytical Laboratories Announces Patent Filings in U.S. for Zika Detection Assays

RICHMOND, British Columbia, August 19, 2016 /PRNewswire/ --

bioLytical Laboratories, a world leader in rapid infectious disease tests, is pleased to announce that it has filed two patent applications with the U.S. Patent and Trademark Office relating to multiple color rapid detection assay systems. The two new patent applications expand the growing intellectual property portfolio for the company and the innovative features that make this an ideal immunoassay system for the detection of antibodies to pathogens including Zika and other flaviviruses.

The two new patent applications are based on the Company's INSTI platform and describe methods and kits allowing either simultaneous or sequential detection of different antibody classes to multiple pathogens using a single sample of blood or blood product. The first patent application describes a method for detecting active or past infection using Zika as an example. The second patent application describes a method for differentiating early from later stages of infection. These technology breakthroughs can revolutionize point-of-care rapid assays for detection of acute infections including Zika.

Rick Galli, Chief Technical Officer, stated, "It is important to have innovative and relevant technologies at a state of readiness to enable a rapid response to emerging infectious diseases like the Zika virus outbreak. This is a vital contribution to disease control measures necessary for effective intervention and disease management practices. These patents represent an important first step in being able to effectively respond to current and future outbreaks."

The Flaviviridae family has become a major concern in many areas of South America and more recently in the continental United States. As of early February 2016, the Brazil Ministry of Health has estimated that 500,000 to 1,500,000 cases of Zika virus disease have occurred since the beginning of the outbreak.^[1] With the high degree of cross-reactivity within the flaviviridae family, a diagnostic assay that can rapidly detect and differentiate between them, and determine new vs old infection, is of upmost importance and is a current area of focus for bioLytical.

About bioLytical Laboratories Inc.  

bioLytical Laboratories Inc. is a privately owned Canadian company engaged in the research, development and commercialization of rapid, point of care in vitro medical diagnostics using its proprietary INSTI technology platform. With a world-wide footprint of regulatory approvals including US FDA approval, Health Canada approval and CE mark, bioLytical markets and sells its INSTI HIV test globally and INSTI HIV/Syphilis Multiplex test in Europe. The INSTI product line provides highly accurate test results in 60 seconds or less, far faster than the 15-20 minutes required for competitors' tests based on lateral flow technology. bioLytical has an active R&D program with a pipeline that includes tests for diseases such as Hepatitis C and Ebola, among others. The company also provides contract services to adapt the INSTI platform to meet custom functional and technical diagnostic testing requirements. For more information, please visit http://www.biolytical.com.

Stan Miele, info@biolytical.com , +1-604-204-6784